DK0995748T3 - Væksthormonsecerneringsfremkaldende stoffer - Google Patents

Væksthormonsecerneringsfremkaldende stoffer

Info

Publication number: DK0995748T3
Authority: DK; Denmark
Prior art keywords: growth hormone; compounds; useful; accelerating; present
Prior art date: 1998-08-21

Application number

DK99306576T

Other languages

English (en)

Inventor

Philip Albert Carpino

Original Assignee

Pfizer Prod Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-08-21

Filing date

1999-08-19

Publication date

2004-08-02

1999-08-19 Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc

2004-08-02 Application granted granted Critical

2004-08-02 Publication of DK0995748T3 publication Critical patent/DK0995748T3/da

Links

102000018997 Growth Hormone Human genes 0.000 title abstract 4
108010051696 Growth Hormone Proteins 0.000 title abstract 4
239000000122 growth hormone Substances 0.000 title abstract 4
239000000411 inducer Substances 0.000 title 1
230000028327 secretion Effects 0.000 title 1
150000001875 compounds Chemical class 0.000 abstract 4
102000038461 Growth Hormone-Releasing Hormone Human genes 0.000 abstract 2
239000000095 Growth Hormone-Releasing Hormone Substances 0.000 abstract 2
208000001132 Osteoporosis Diseases 0.000 abstract 2
RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 abstract 2
101710142969 Somatoliberin Proteins 0.000 abstract 2
229940011871 estrogen Drugs 0.000 abstract 2
239000000262 estrogen Substances 0.000 abstract 2
230000013632 homeostatic process Effects 0.000 abstract 2
239000008194 pharmaceutical composition Substances 0.000 abstract 2
102000004169 proteins and genes Human genes 0.000 abstract 2
108090000623 proteins and genes Proteins 0.000 abstract 2
DNXHEGUUPJUMQT-UHFFFAOYSA-N (+)-estrone Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 DNXHEGUUPJUMQT-UHFFFAOYSA-N 0.000 abstract 1
NWQWNCILOXTTHF-HLCSKTDOSA-N (2s)-6-amino-2-[[(2r)-2-[[(2s)-2-[[(2s)-2-[[(2r)-2-[[(2s)-2-[[(2s)-2-aminopropanoyl]amino]-3-(1h-imidazol-5-yl)propanoyl]amino]-3-naphthalen-2-ylpropanoyl]amino]propanoyl]amino]-3-(1h-indol-3-yl)propanoyl]amino]-3-phenylpropanoyl]amino]hexanamide Chemical compound C([C@H](NC(=O)[C@@H](N)C)C(=O)N[C@H](CC=1C=C2C=CC=CC2=CC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCCN)C(N)=O)C1=CNC=N1 NWQWNCILOXTTHF-HLCSKTDOSA-N 0.000 abstract 1
WZHKXNSOCOQYQX-FUAFALNISA-N (2s)-6-amino-2-[[(2r)-2-[[(2s)-2-[[(2s)-2-[[(2r)-2-[[(2s)-2-amino-3-(1h-imidazol-5-yl)propanoyl]amino]-3-(1h-indol-3-yl)propanoyl]amino]propanoyl]amino]-3-(1h-indol-3-yl)propanoyl]amino]-3-phenylpropanoyl]amino]hexanamide Chemical compound C([C@H](N)C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCCN)C(N)=O)C1=CN=CN1 WZHKXNSOCOQYQX-FUAFALNISA-N 0.000 abstract 1
RVWNMGKSNGWLOL-GIIHNPQRSA-N (2s)-6-amino-2-[[(2r)-2-[[(2s)-2-[[(2s)-2-[[(2r)-2-[[(2s)-2-amino-3-(1h-imidazol-5-yl)propanoyl]amino]-3-(2-methyl-1h-indol-3-yl)propanoyl]amino]propanoyl]amino]-3-(1h-indol-3-yl)propanoyl]amino]-3-phenylpropanoyl]amino]hexanamide Chemical compound C([C@H](N)C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCCN)C(N)=O)C1=CN=CN1 RVWNMGKSNGWLOL-GIIHNPQRSA-N 0.000 abstract 1
DHSSDEDRBUKTQY-UHFFFAOYSA-N 6-prop-2-enyl-4,5,7,8-tetrahydrothiazolo[4,5-d]azepin-2-amine Chemical compound C1CN(CC=C)CCC2=C1N=C(N)S2 DHSSDEDRBUKTQY-UHFFFAOYSA-N 0.000 abstract 1
OGSPWJRAVKPPFI-UHFFFAOYSA-N Alendronic Acid Chemical compound NCCCC(O)(P(O)(O)=O)P(O)(O)=O OGSPWJRAVKPPFI-UHFFFAOYSA-N 0.000 abstract 1
102100033367 Appetite-regulating hormone Human genes 0.000 abstract 1
101710111255 Appetite-regulating hormone Proteins 0.000 abstract 1
229940122361 Bisphosphonate Drugs 0.000 abstract 1
208000010392 Bone Fractures Diseases 0.000 abstract 1
206010006895 Cachexia Diseases 0.000 abstract 1
102000055006 Calcitonin Human genes 0.000 abstract 1
108060001064 Calcitonin Proteins 0.000 abstract 1
206010007559 Cardiac failure congestive Diseases 0.000 abstract 1
208000017667 Chronic Disease Diseases 0.000 abstract 1
208000036119 Frailty Diseases 0.000 abstract 1
206010019280 Heart failures Diseases 0.000 abstract 1
108090000723 Insulin-Like Growth Factor I Proteins 0.000 abstract 1
102000004218 Insulin-Like Growth Factor I Human genes 0.000 abstract 1
102000048143 Insulin-Like Growth Factor II Human genes 0.000 abstract 1
108090001117 Insulin-Like Growth Factor II Proteins 0.000 abstract 1
208000008589 Obesity Diseases 0.000 abstract 1
230000032683 aging Effects 0.000 abstract 1
239000000556 agonist Substances 0.000 abstract 1
108010083553 alanyl-histidyl-(2-naphthyl)alanyl-tryptophyl-phenylalanyl-lysinamide Proteins 0.000 abstract 1
229940062527 alendronate Drugs 0.000 abstract 1
239000005557 antagonist Substances 0.000 abstract 1
206010003549 asthenia Diseases 0.000 abstract 1
-1 bisphosphonate compound Chemical class 0.000 abstract 1
229960004015 calcitonin Drugs 0.000 abstract 1
BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 abstract 1
230000001925 catabolic effect Effects 0.000 abstract 1
JKKFKPJIXZFSSB-CBZIJGRNSA-N estrone 3-sulfate Chemical compound OS(=O)(=O)OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 JKKFKPJIXZFSSB-CBZIJGRNSA-N 0.000 abstract 1
108010015153 growth hormone releasing hexapeptide Proteins 0.000 abstract 1
239000003324 growth hormone secretagogue Substances 0.000 abstract 1
108010070965 hexarelin Proteins 0.000 abstract 1
230000002503 metabolic effect Effects 0.000 abstract 1
210000003205 muscle Anatomy 0.000 abstract 1
235000020824 obesity Nutrition 0.000 abstract 1
229940063238 premarin Drugs 0.000 abstract 1
230000002265 prevention Effects 0.000 abstract 1
239000000186 progesterone Substances 0.000 abstract 1
229960003387 progesterone Drugs 0.000 abstract 1
238000011084 recovery Methods 0.000 abstract 1
230000004044 response Effects 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
238000001356 surgical procedure Methods 0.000 abstract 1
230000029663 wound healing Effects 0.000 abstract 1
229940126158 β3 adrenergic receptor agonist Drugs 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Physical Education & Sports Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Orthopedic Medicine & Surgery (AREA)
Rheumatology (AREA)
Endocrinology (AREA)
Dermatology (AREA)
Diabetes (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Medicinal Preparation (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

DK99306576T 1998-08-21 1999-08-19 Væksthormonsecerneringsfremkaldende stoffer DK0995748T3 (da)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US9750298P	1998-08-21	1998-08-21

Publications (1)

Publication Number	Publication Date
DK0995748T3 true DK0995748T3 (da)	2004-08-02

Family

ID=22263698

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK99306576T DK0995748T3 (da)	1998-08-21	1999-08-19	Væksthormonsecerneringsfremkaldende stoffer

Country Status (11)

Country	Link
US (3)	US6358951B1 (da)
EP (1)	EP0995748B1 (da)
JP (1)	JP3486137B2 (da)
AT (1)	ATE263168T1 (da)
BR (1)	BR9903870A (da)
CA (2)	CA2280587C (da)
DE (1)	DE69915968T2 (da)
DK (1)	DK0995748T3 (da)
ES (1)	ES2217694T3 (da)
MX (1)	MXPA03006951A (da)
PT (1)	PT995748E (da)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6358951B1 (en)	1998-08-21	2002-03-19	Pfizer Inc.	Growth hormone secretagogues
US6297380B1 (en) *	1998-11-23	2001-10-02	Pfizer Inc.	Process and intermediates for growth hormone secretagogues
PT1268453E (pt)	2000-04-07	2006-10-31	Pfizer Prod Inc	Metabolitos de agonista/antagonista de estrogenio
AU2001264977B2 (en) *	2000-05-30	2005-04-14	Merck & Co., Inc.	Melanocortin receptor agonists
ATE446758T1 (de)	2000-05-31	2009-11-15	Pfizer Prod Inc	Verwendung von wachstumshormonsekretagoga zur förderung der beweglichkeit des verdauungstrakts
IL143690A0 (en) *	2000-06-19	2002-04-21	Pfizer Prod Inc	The use of growth hormone secretagogues to treat systemic lupus erythematosus and inflammatory bowel disease
EP1181933A3 (en) *	2000-06-29	2002-04-10	Pfizer Products Inc.	Use of growth hormone secretagogues for stimulating or increasing appetite
IL143942A0 (en) *	2000-06-29	2002-04-21	Pfizer Prod Inc	Use of growth hormone secretagogues for treatment of physical performance decline
IL144468A0 (en) *	2000-07-27	2002-05-23	Pfizer Prod Inc	Use of growth hormone secretagogues for improvement of functional health status
IL145106A0 (en) *	2000-08-30	2002-06-30	Pfizer Prod Inc	Intermittent administration of a geowth hormone secretagogue
IL145540A0 (en) *	2000-09-28	2002-06-30	Pfizer Prod Inc	Use of growth hormone secretagogues in conjunction with physical exercise
CA2372450A1 (en) *	2001-05-10	2001-09-19	Pharmaceutical Partners Of Canada Inc.	Liquid injectable formulation of disodium pamidronate
IL159270A0 (en) *	2001-06-14	2004-06-01	Yissum Res Dev Co	Non-myeloablative tolerogenic treatment with tyrphostins
US7105526B2 (en)	2002-06-28	2006-09-12	Banyu Pharmaceuticals Co., Ltd.	Benzimidazole derivatives
US7772188B2 (en)	2003-01-28	2010-08-10	Ironwood Pharmaceuticals, Inc.	Methods and compositions for the treatment of gastrointestinal disorders
US7476653B2 (en)	2003-06-18	2009-01-13	Tranzyme Pharma, Inc.	Macrocyclic modulators of the ghrelin receptor
US20050107350A1 (en) *	2003-08-22	2005-05-19	Pharmacia Corporation	Method for the treatment or prevention of bone disorders with a cyclooxygenase-2 inhibitor alone and in combination with a bone disorder treatment agent and compositions therewith
JP2005306839A (ja) *	2003-08-29	2005-11-04	Takeda Chem Ind Ltd	二環性ピペラジン化合物およびその用途
EP1661898A4 (en)	2003-08-29	2009-04-15	Takeda Pharmaceutical	BICYCLIC PIPERAZINE COMPOUND AND ITS USE
JP4765627B2 (ja)	2003-09-22	2011-09-07	Ｍｓｄ株式会社	新規ピペリジン誘導体
CA2544602A1 (en) *	2003-11-04	2005-05-26	Elixir Pharmaceuticals, Inc.	Therapeutic compounds and uses thereof
EP1529533A1 (en) *	2003-11-06	2005-05-11	Sahltech I Göteborg AB	Use of GH secretagogues in hypoxic-ischemic brain injury
US20080125403A1 (en)	2004-04-02	2008-05-29	Merck & Co., Inc.	Method of Treating Men with Metabolic and Anthropometric Disorders
WO2005097788A2 (en) *	2004-04-02	2005-10-20	Elixir Pharmaceuticals, Inc.	Sulfonamides and uses thereof
CA2577060A1 (en) *	2004-08-13	2006-02-23	Amgen Inc.	Substituted benzofused heterocycles
US8138206B2 (en)	2005-05-30	2012-03-20	Msd. K.K.	Piperidine derivative
CA2618112A1 (en)	2005-08-10	2007-02-15	Banyu Pharmaceutical Co., Ltd.	Pyridone compound
WO2007024004A1 (ja)	2005-08-24	2007-03-01	Banyu Pharmaceutical Co., Ltd.	フェニルピリドン誘導体
AU2006288153A1 (en)	2005-09-07	2007-03-15	Msd K.K.	Bicyclic aromatic substituted pyridone derivative
KR20080048502A (ko)	2005-09-29	2008-06-02	머크 앤드 캄파니 인코포레이티드	멜라노코르틴-4 수용체 조절제로서의 아실화스피로피페리딘 유도체
RU2008119687A (ru)	2005-10-21	2009-11-27	Новартис АГ (CH)	Комбинации органических соединений
CA2627139A1 (en)	2005-10-27	2007-05-03	Banyu Pharmaceutical Co., Ltd.	Novel benzoxathiin derivative
ES2381205T3 (es)	2005-11-10	2012-05-24	Msd K.K.	Derivado espiro aza-sustituido
CU23558A1 (es)	2006-02-28	2010-07-20	Ct Ingenieria Genetica Biotech	Compuestos análogos a los secretagogos peptidicos de la hormona de crecimiento
PE20080145A1 (es) *	2006-03-21	2008-02-11	Janssen Pharmaceutica Nv	Tetrahidro-pirimidoazepinas como moduladores de trpv1
EP2039695A4 (en) *	2006-07-11	2010-09-15	Takeda Pharmaceutical	BICYCLIC HETEROCYLIC COMPOUND AND ITS USE
GB0618082D0 (en) *	2006-09-14	2006-10-25	Asterion Ltd	Growth factor
US8173629B2 (en)	2006-09-22	2012-05-08	Merck Sharp & Dohme Corp.	Method of treatment using fatty acid synthesis inhibitors
WO2008047544A1 (en)	2006-09-28	2008-04-24	Banyu Pharmaceutical Co., Ltd.	Diaryl ketimine derivative
CA2677399C (en)	2007-02-09	2016-09-13	Tranzyme Pharma, Inc.	Macrocyclic ghrelin receptor modulators and methods of using the same
US8969514B2 (en)	2007-06-04	2015-03-03	Synergy Pharmaceuticals, Inc.	Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
MX2009013293A (es)	2007-06-04	2010-02-15	Synergy Pharmaceuticals Inc	Agonistas de guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos.
US7994127B2 (en) *	2007-06-08	2011-08-09	Massachusetts Institute Of Technology	Treatment of rett syndrome
WO2009078999A1 (en)	2007-12-17	2009-06-25	Janssen Pharmaceutica N.V.	Imidazolo-, oxazolo-, and thiazolopyrimidine modulators of trpv1
JPWO2009110510A1 (ja)	2008-03-06	2011-07-14	Ｍｓｄ株式会社	アルキルアミノピリジン誘導体
US20110015198A1 (en)	2008-03-28	2011-01-20	Banyu Pharmaceutical Co., Inc.	Diarylmethylamide derivative having melanin-concentrating hormone receptor antagonism
EP2810951B1 (en)	2008-06-04	2017-03-15	Synergy Pharmaceuticals Inc.	Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
JPWO2009154132A1 (ja)	2008-06-19	2011-12-01	Ｍｓｄ株式会社	スピロジアミン−ジアリールケトオキシム誘導体
CA2730603C (en)	2008-07-16	2019-09-24	Synergy Pharmaceuticals Inc.	Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
JPWO2010013595A1 (ja)	2008-07-30	2012-01-12	Ｍｓｄ株式会社	５員−５員又は５員−６員縮環シクロアルキルアミン誘導体
EP2348857B1 (en)	2008-10-22	2016-02-24	Merck Sharp & Dohme Corp.	Novel cyclic benzimidazole derivatives useful anti-diabetic agents
EP2350010B1 (en)	2008-10-30	2014-03-26	Merck Sharp & Dohme Corp.	Isonicotinamide orexin receptor antagonists
JP5557845B2 (ja)	2008-10-31	2014-07-23	メルク・シャープ・アンド・ドーム・コーポレーション	糖尿病用剤として有用な新規環状ベンゾイミダゾール誘導体
AU2011218830B2 (en)	2010-02-25	2014-07-24	Merck Sharp & Dohme Corp.	Novel cyclic benzimidazole derivatives useful anti-diabetic agents
US9616097B2 (en)	2010-09-15	2017-04-11	Synergy Pharmaceuticals, Inc.	Formulations of guanylate cyclase C agonists and methods of use
WO2012037519A2 (en) *	2010-09-16	2012-03-22	University Of Miami	Acceleration of wound healing by growth hormone releasing hormone and its agonists
MX348131B (es)	2011-02-25	2017-05-26	Merck Sharp & Dohme	Novedosos derivados de azabencimidazol ciclico utiles como agentes antidiabeticos.
AR088352A1 (es)	2011-10-19	2014-05-28	Merck Sharp & Dohme	Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina
WO2014022528A1 (en)	2012-08-02	2014-02-06	Merck Sharp & Dohme Corp.	Antidiabetic tricyclic compounds
WO2014130608A1 (en)	2013-02-22	2014-08-28	Merck Sharp & Dohme Corp.	Antidiabetic bicyclic compounds
WO2014139388A1 (en)	2013-03-14	2014-09-18	Merck Sharp & Dohme Corp.	Novel indole derivatives useful as anti-diabetic agents
JP2016514671A (ja)	2013-03-15	2016-05-23	シナジーファーマシューティカルズインコーポレイテッド	グアニル酸シクラーゼのアゴニストおよびその使用
JP2016514670A (ja)	2013-03-15	2016-05-23	シナジーファーマシューティカルズインコーポレイテッド	他の薬物と組み合わせたグアニル酸シクラーゼ受容体アゴニスト
EA201592263A1 (ru)	2013-06-05	2016-05-31	Синерджи Фармасьютикалз, Инк.	Ультрачистые агонисты гуанилатциклазы c, способ их получения и использования
WO2015051496A1 (en)	2013-10-08	2015-04-16	Merck Sharp & Dohme Corp.	Antidiabetic tricyclic compounds
EP3186242B1 (en)	2014-08-29	2021-10-06	Tes Pharma S.r.l.	Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase
US10774043B2 (en)	2016-05-06	2020-09-15	Council Of Scientific & Industrial Research	Glycolactam compounds, process for preparation and uses thereof
AU2017342083A1 (en)	2016-10-14	2019-04-11	Tes Pharma S.R.L.	Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase
US11072602B2 (en)	2016-12-06	2021-07-27	Merck Sharp & Dohme Corp.	Antidiabetic heterocyclic compounds
EP3558298B1 (en)	2016-12-20	2026-03-11	Merck Sharp & Dohme LLC	Antidiabetic spirochroman compounds
AR117122A1 (es)	2018-11-20	2021-07-14	Tes Pharma S R L	INHIBIDORES DE LA ÁCIDO a-AMINO-b-CARBOXIMUCÓNICO SEMIALDEHÍDO DESCARBOXILASA
EP3923933A4 (en)	2019-02-13	2022-08-17	Merck Sharp & Dohme Corp.	PYRROLIDINOREXINE RECEPTOR AGONISTS
TW202045476A (zh)	2019-02-13	2020-12-16	美商默沙東藥廠	5-烷基吡咯啶食慾素受體促效劑
WO2021026047A1 (en)	2019-08-08	2021-02-11	Merck Sharp & Dohme Corp.	Heteroaryl pyrrolidine and piperidine orexin receptor agonists
MX2023001840A (es)	2020-08-18	2023-03-13	Merck Sharp & Dohme Llc	Agonistas de bicicloheptano pirrolidina de los receptores de orexina.
WO2025193784A1 (en) *	2024-03-12	2025-09-18	Lumos Pharma, Inc.	Pharmaceutical formulations for maintaining lean muscle mass during weight loss treatment

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4411890A (en)	1981-04-14	1983-10-25	Beckman Instruments, Inc.	Synthetic peptides having pituitary growth hormone releasing activity
CA2147503A1 (en)	1992-11-06	1994-05-26	Judith M. Pisano	Substituted dipeptide analogs promote release of growth hormone
WO1994013696A1 (en)	1992-12-11	1994-06-23	Merck & Co., Inc.	Spiro piperidines and homologs which promote release of growth hormone
EP0828754B1 (en)	1995-05-29	2005-02-02	Pfizer Inc.	Dipeptides which promote release of growth hormone
EP0766966A3 (en)	1995-09-08	2001-02-28	Eli Lilly And Company	Method of treating insulin resistance
TW432073B (en)	1995-12-28	2001-05-01	Pfizer	Pyrazolopyridine compounds
DE69734215T2 (de)	1996-07-22	2006-06-29	Novo Nordisk A/S	Verbindungen mit Wachstumshormon-freisetzenden Eigenschaften
WO1998010653A1 (en)	1996-09-13	1998-03-19	Merck & Co., Inc.	Piperidines, pyrrolidines and hexahydro-1h-azepines promote release of growth hormone
AU5599898A (en)	1996-12-12	1998-07-03	Merck & Co., Inc.	Piperidines, pyrrolidines and hexahydro-1h-azepines promote release of growth hormone
JP3514774B2 (ja)	1997-06-25	2004-03-31	ファイザー・インク	成長ホルモン分泌促進薬としてのジペプチド誘導体
US6358951B1 (en)	1998-08-21	2002-03-19	Pfizer Inc.	Growth hormone secretagogues

1999
- 1999-08-18 US US09/377,326 patent/US6358951B1/en not_active Expired - Fee Related
- 1999-08-19 AT AT99306576T patent/ATE263168T1/de not_active IP Right Cessation
- 1999-08-19 CA CA002280587A patent/CA2280587C/en not_active Expired - Fee Related
- 1999-08-19 CA CA002420425A patent/CA2420425A1/en not_active Abandoned
- 1999-08-19 DE DE69915968T patent/DE69915968T2/de not_active Expired - Fee Related
- 1999-08-19 ES ES99306576T patent/ES2217694T3/es not_active Expired - Lifetime
- 1999-08-19 DK DK99306576T patent/DK0995748T3/da active
- 1999-08-19 PT PT99306576T patent/PT995748E/pt unknown
- 1999-08-19 EP EP99306576A patent/EP0995748B1/en not_active Expired - Lifetime
- 1999-08-20 BR BR9903870-6A patent/BR9903870A/pt not_active Application Discontinuation
- 1999-08-20 JP JP23470499A patent/JP3486137B2/ja not_active Expired - Fee Related
2001
- 2001-11-21 US US09/989,040 patent/US6559150B2/en not_active Expired - Fee Related
2002
- 2002-12-06 US US10/313,495 patent/US6686359B2/en not_active Expired - Fee Related
2003
- 2003-08-04 MX MXPA03006951A patent/MXPA03006951A/es unknown

Also Published As

Publication number	Publication date
US20030130284A1 (en)	2003-07-10
CA2280587C (en)	2004-09-21
CA2280587A1 (en)	2000-02-21
US6686359B2 (en)	2004-02-03
ATE263168T1 (de)	2004-04-15
DE69915968T2 (de)	2005-03-10
BR9903870A (pt)	2000-10-03
US20020045622A1 (en)	2002-04-18
US6358951B1 (en)	2002-03-19
JP2000072771A (ja)	2000-03-07
DE69915968D1 (de)	2004-05-06
EP0995748A1 (en)	2000-04-26
ES2217694T3 (es)	2004-11-01
MXPA03006951A (es)	2003-12-08
PT995748E (pt)	2004-07-30
JP3486137B2 (ja)	2004-01-13
CA2420425A1 (en)	2000-02-21
EP0995748B1 (en)	2004-03-31
US6559150B2 (en)	2003-05-06

Publication	Publication Date	Title
PT995748E (pt)	2004-07-30	Secretagogos da hormona do crescimento
MY135727A (en)	2008-06-30	Heterocyclic compounds.
AP9801270A0 (en)	1999-12-18	Dipeptide derivatives.
DK1002802T3 (da)	2005-03-14	Dipeptidderivater som væksthormonsecerneringsfremkaldende stoffer
AP1043A (en)	2002-02-04	Tartrate salt of a substituted dipeptide.
JP4932132B2 (ja)	2012-05-16	成長ホルモン分泌促進薬
US20020077281A1 (en)	2002-06-20	Fracture healing using pthrp analogs
US20080045504A1 (en)	2008-02-21	Benzonitrile Derivatives to Treat Musculoskeletal Frailty
YU44041B (en)	1990-02-28	Process for obtaining mammalian pgrf peptides
JP2011514376A (ja)	2011-05-06	新規の１，２，４−トリアゾール誘導体およびそれらの製造方法
EP1592434A1 (en)	2005-11-09	Conformationally constrained parathyroid hormone (pth) analogs with lactam bridges
US7038010B2 (en)	2006-05-02	Agents and methods for promoting bone growth
US7034050B2 (en)	2006-04-25	Pseudopeptides growth hormone secretagogues
US6211174B1 (en)	2001-04-03	Naphtho-fused lactams promote release of growth hormone
HUP0202167A2 (en)	2002-10-28	Calcilytic compounds
CN100343276C (zh)	2007-10-17	骨形成刺激剂、其合成方法及用途
WO2002056873A2 (en)	2002-07-25	2-substituted dibenzo[a,e]1,2,3-triazolo[4,5-c][7]annulen-8-ones as growth hormone secretagogues
EP1756142A1 (en)	2007-02-28	Pseudopeptides growth hormone secretagogues
MXPA99012100A (en)	2000-09-04	Tartrate salt of a substituted dipeptide as growth hormone secretagogue